1. bookVolumen 61 (2011): Edición 1 (March 2011)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
ISSN
1330-0075
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Synthesis and cAMP-dependent phosphodiesterase inhibition of novel thiazoloquinazoline derivatives

Publicado en línea: 15 Mar 2011
Volumen & Edición: Volumen 61 (2011) - Edición 1 (March 2011)
Páginas: 103 - 113
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
ISSN
1330-0075
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

W. J. Roesler, J. G. Graham, R. Kolen, D. J. Klemm and P. J. Mc Fie, The cAMP response element binding protein synergies with other transcription factors to mediate cAMP responsiveness, J. Biol. Chem. 270 (1995) 8225-8232; DOI: 10.1074/jbc270.14.8225.Search in Google Scholar

G. S. McKnight, Cyclic AMP second messenger system, Curr. Opin. Cell Biol. 3 (1991) 213-217.10.1016/0955-0674(91)90141-KSearch in Google Scholar

S. S. Taylor, S. A. Buechler and W. Yonemoto, cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes, Annu. Rev. Biochem. 59 (1990) 971-1005.Search in Google Scholar

R. W. Butcher and E. W. Sutherland, Adenosine 3,5-phosphate in biological materials. I. Purification and properties of cyclic 3,5-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3,5-phosphate in human urine, J. Biol. Chem. 237 (1962) 1244-1250.10.1016/S0021-9258(18)60316-3Search in Google Scholar

A. Hatzelmann, E. J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, R. Beume, C. Schudt and H. Tenor, The preclinical pharmacology of roflumilaste - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease, Pulm. Pharmacol. Ther. 23 (2010) 235-256; DOI: 10.1016/j.pupt.2010.03.011.10.1016/j.pupt.2010.03.01120381629Search in Google Scholar

W. Jiang, J. Guan, M. J. Macielag, S. Zhang, Y. Qiu, P. Kraft, S. Bhattacharjee, T. M. John, D. H. Johnson, S. Lundeen and Z. Sui, Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction, J. Med. Chem. 48 (2005) 2126-2133; DOI: 10.1021/jm0401098.10.1021/jm040109815771456Search in Google Scholar

A. Daugan, P. Grondin, C. Ruault, A. C. Le Monnier de Gouville, H. Coste, J. Kirilovsky, F. Hyafil and R. Labaudinière, The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-Tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3 (2H)-dione Analogues, J. Med. Chem. 46 (2003) 4525-4532; DOI: 10.1021/jm030056e.10.1021/jm030056e14521414Search in Google Scholar

A. Daugan, P. Grondin, C. Ruault, H. Coste, J. Kirilovsky, F. Hyafil and R. Labaudinière, The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 2: 2, 3, 6, 7, 12, 12a-hexahydropyrazino [1',2':1,6] pyrido[3,4-b] indole-1,4-dione analogues, J. Med. Chem. 46 (2003) 4533-4542; DOI: 10.1021/jm0300577.10.1021/jm030057714521415Search in Google Scholar

A. Martínez, A. Castro, C. Gil, M. Miralpeix, V. Segarra, T. Doménech, J. Beleta, J. M. Palacios, H. Ryder, X. Miró, C. Bonet, J. M. Casacuberta, F. Azorín, B. Piña and P. Puigdoménech, Benzyl derivatives of 2, 1, 3-benzo- and benzothieno [3,2-a] thiadiazine 2,2-dioxides: First phosphodiesterase 7 inhibitors, J. Med. Chem. 43 (2000) 683-689; DOI: 10.1021/jm990382n.10.1021/jm990382n10691694Search in Google Scholar

A. J. Duplantier, C. J. Andresen, J. B. Cheng, V. L. Cohan, C. Decker, F. M. DiCapua, K. G. Kraus, K. L. Johnson, J. W. Watson, R. T. Wester and A. S. Williams, 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridines as novel inhibitors of human eosinophil phosphodiesterase, J. Med. Chem. 41 (1998) 2268-2277; DOI: 10.1021/jm9800090.10.1021/jm98000909632360Search in Google Scholar

D. P. Rotella, Z. Sun, Y. Zhu, J. Krupinski, R. Pongrac, L. Seliger, D. Normandin and J. E. Macor, N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction, J. Med. Chem. 43 (2000) 1257-1263. DOI: 10.1021/jm000081+.10.1021/jm000081+10753463Search in Google Scholar

D. P. Rotella, Z. Sun, Y. Zhu, J. Krupinski, R. Pongrac, L. Seliger, D. Normandin and J. E. Macor, Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors, J. Med. Chem. 43 (2000) 5037-5043; DOI: 10.1021/jm000336j.10.1021/jm000336j11150175Search in Google Scholar

A. A. Bekhit, N. S. Habib and A. El-Din, Synthesis and antimicrobial evaluation of chalcone and syndrome derivatives of 4(3H)-quinazolinone, Boll. Chim. Farm. 140 (2001) 297-301.Search in Google Scholar

B. Maggio, G. Daidone and D. Raffa, Synthesis and pharmacological study of ethyl 1-methyl-5-(substituted 3,4-dihydro-4-oxoquinazolin-3-yl)-1H-pyrazole-4-acetates, Eur. J. Med. Chem. 36 (2001) 737-742.10.1016/S0223-5234(01)01259-4Search in Google Scholar

B. Lasztoczi, R. Kovacs and L. Nyikos, A glutamate receptor subtype antagonist inhibits seizures in rat hippocampal slices, Neuroreport 13 (2002) 351-356.10.1097/00001756-200203040-0002011930136Search in Google Scholar

A. Lopez-Farre, J. A. Rodriguez-Feo and E. Garcia-Colis, Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats effect of the alpha1-receptor blocker doxazosin, J. Hypertens. 20 (2002) 463-470.10.1097/00004872-200203000-0002211875314Search in Google Scholar

R. Sharma, S. Kumar and H. K. Pujari, Reaction of 3,4,5,6,7,8-hexahydro-4-phenylquinazoline-2-thione with chloroacetic acid, Indian J. Chem. 30B (1991) 425-426.Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo